Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Nov. 9-21. Deal Watch is supported by deal intelligence from Strategic Transactions.
Bristol-Myers Squibb Co. is making a move into the fast-moving gut microbiome space in an immuno-oncology focused collaboration with...